Literature DB >> 27761711

Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.

Jin Sil Kim1, Hyun Jin Kim2, Seong Ho Park1, Jong Seok Lee1, Ah Young Kim1, Hyun Kwon Ha1.   

Abstract

OBJECTIVES: To evaluate the CT features of ruptured GISTs and factors that might be predictive of rupture through comparison with CTs taken prior to rupture and CTs of non-ruptured GIST.
METHODS: Forty-nine patients with ruptured GIST and forty-nine patients with non-ruptured GIST matched by age, gender and location were included. Clinical data including pharmacotherapy were reviewed. The imaging features were analyzed. Prior CT obtained before rupture were evaluated.
RESULTS: The most common location of ruptured GIST was small bowel with mean size of 12.1 cm. Ruptured GIST commonly showed wall defects, >40 % eccentric necrosis, lobulated shaped, air density in mass, pneumoperitoneum, peritonitis, hemoperitoneum and ascites (p < 0.001-0.030). Twenty-seven of 30 patients with follow up imaging received targeted therapy. During follow-up, thickness of the tumour wall decreased. Increase in size and progression of necrosis were common during targeted therapy (p = 0.017). Newly developed ascites, peritonitis and hemoperitoneum was more common (p < 0.001-0.036).
CONCLUSION: Ruptured GISTs commonly demonstrate large size, >40 % eccentric necrosis, wall defects and lobulated shape. The progression of necrosis with increase in size and decreased wall thickness during targeted therapy may increase the risk of rupture. Rupture should be considered when newly developed peritonitis, hemoperitoneum, or ascites are noted during the follow-up. KEY POINTS: • Ruptured GISTs demonstrate large size, eccentric necrosis, wall defects, and lobulated shape. • Rupture should be considered when peritonitis or hemoperitoneum/adjacent hematoma newly appears. • Progression of necrosis with increase in size increases the risk of rupture.

Entities:  

Keywords:  Computed tomography; Diagnostic imaging; Gastrointestinal stromal tumours; Intestinal neoplasm; Rupture

Mesh:

Substances:

Year:  2016        PMID: 27761711     DOI: 10.1007/s00330-016-4515-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

1.  Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour.

Authors:  Cuiping Zhou; Xiaohui Duan; Xiang Zhang; Huijun Hu; Dongye Wang; Jun Shen
Journal:  Eur Radiol       Date:  2015-12-23       Impact factor: 5.315

2.  1189 Gastrointestinal stromal tumor (GIST): computed tomographic features and correlation of CT findings with histologic grade.

Authors:  Siripom Pinaikul; Piyanoot Woodtichartpreecha; Samornmas Kanngurn; Sombat Leelakiatpaiboon
Journal:  J Med Assoc Thai       Date:  2014-11

Review 3.  Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.

Authors:  Asmaa E El-Kenawi; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 5.  Neoplastic and inflammatory processes of the peritoneum, omentum, and mesentery: diagnosis with CT.

Authors:  J E Hamrick-Turner; M V Chiechi; P L Abbitt; P R Ros
Journal:  Radiographics       Date:  1992-11       Impact factor: 5.333

6.  Gastrointestinal stromal tumors: computed tomographic features and prediction of malignant risk from computed tomographic imaging.

Authors:  Tzu-Hsien Yang; Jen-I Hwang; Ming-Shiang Yang; Siu-Wan Hung; Si-Wa Chan; John Wang; Yeu-Sheng Tyan
Journal:  J Chin Med Assoc       Date:  2007-09       Impact factor: 2.743

7.  [Clinical pathological features and prognosis analysis of gastrointestinal stromal tumor: a series of 558 cases].

Authors:  Jian Yang; Jianchun Yu; Zhiqiang Ma; Weiming Kang; Shubo Tian; Xin Ye
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2015-04

8.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

9.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466

Review 10.  Spontaneous rupture of a giant gastrointestinal stromal tumor of the jejunum: a case report and literature review.

Authors:  Shun-ichi Misawa; Misuzu Takeda; Hiroto Sakamoto; Yasushi Kirii; Hiroyoshi Ota; Hiroyuki Takagi
Journal:  World J Surg Oncol       Date:  2014-05-21       Impact factor: 2.754

View more
  9 in total

1.  The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm.

Authors:  Tao Chen; Lili Xu; Xiaoyu Dong; Yue Li; Jiang Yu; Wei Xiong; Guoxin Li
Journal:  Eur Radiol       Date:  2019-01-07       Impact factor: 5.315

Review 2.  Gastrointestinal stromal tumors: a comprehensive radiological review.

Authors:  Akitoshi Inoue; Shinichi Ota; Michio Yamasaki; Bolorkhand Batsaikhan; Akira Furukawa; Yoshiyuki Watanabe
Journal:  Jpn J Radiol       Date:  2022-07-09       Impact factor: 2.374

3.  Primary gastric squamous cell carcinoma presenting as a large submucosal mass: A case report and literature review.

Authors:  Lei Gao; Xiaolong Tang; Hui Qu; Qingsi He; Guorui Sun; Jingbo Shi; Jianhong Ye; Yahang Liang
Journal:  Medicine (Baltimore)       Date:  2020-09-04       Impact factor: 1.889

Review 4.  Gastrointestinal stromal tumors: A multidisciplinary challenge.

Authors:  Juan Manuel Sanchez-Hidalgo; Manuel Duran-Martinez; Rafael Molero-Payan; Sebastian Rufian-Peña; Alvaro Arjona-Sanchez; Angela Casado-Adam; Antonio Cosano-Alvarez; Javier Briceño-Delgado
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

5.  Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification.

Authors:  Cui Feng; Fangfang Lu; Yaqi Shen; Anqin Li; Hao Yu; Hao Tang; Zhen Li; Daoyu Hu
Journal:  Cancer Imaging       Date:  2018-12-05       Impact factor: 3.909

Review 6.  Current and Potential Applications of Artificial Intelligence in Gastrointestinal Stromal Tumor Imaging.

Authors:  Cai-Wei Yang; Xi-Jiao Liu; Si-Yun Liu; Shang Wan; Zheng Ye; Bin Song
Journal:  Contrast Media Mol Imaging       Date:  2020-11-26       Impact factor: 3.161

7.  Preoperative prediction of gastrointestinal stromal tumors with high Ki-67 proliferation index based on CT features.

Authors:  Cai-Wei Yang; Xi-Jiao Liu; Lian Zhao; Feng Che; Yuan Yin; Hui-Jiao Chen; Bo Zhang; Min Wu; Bin Song
Journal:  Ann Transl Med       Date:  2021-10

8.  Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy.

Authors:  Jaffar Khan; Asad Ullah; Abdul Waheed; Nabin Raj Karki; Nawaraj Adhikari; Lakshmi Vemavarapu; Sami Belakhlef; Samy Malik Bendjemil; Siamak Mehdizadeh Seraj; Feroze Sidhwa; Intisar Ghleilib; Shahin Foroutan; Andrew M Blakely; Jaydira Del Rivero; Nagla Abdel Karim; Eric Vail; Saleh Heneidi; Hector Mesa
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

9.  Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.

Authors:  Toshirou Nishida; Haruhiko Cho; Seiichi Hirota; Toru Masuzawa; Gaku Chiguchi; Toshimasa Tsujinaka
Journal:  Ann Surg Oncol       Date:  2018-05-11       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.